UCB's Global Corporate Website

This section is intended for media and financial analysts

Disposal of own shares

Brussels (Belgium), 11 April 2022 – 20:00 (CEST) – Regulated information 

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:


In addition to these exercises, on 1 April 2022, in accordance with the vesting rules under its 2019 LTI plan, UCB SA/NV has delivered for free a total of 444 712 UCB shares OTC to 1 511 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 1 April 2022 was € 109.10.

This press release is available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14

Corporate Communications
Laurent Schots 
T+32 2 559 92 64

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news


Asset Download

Stay up-to-date on the latest news and information from UCB